Strensiq
Total Payments
$4.7M
Transactions
18,054
Doctors
7,562
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $214,014 | 3,825 | 2,393 |
| 2020 | $622,935 | 2,387 | 1,306 |
| 2019 | $738,992 | 4,025 | 2,266 |
| 2018 | $957,721 | 3,449 | 1,647 |
| 2017 | $2.2M | 4,368 | 2,215 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 1,013 | 43.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $846,839 | 486 | 17.9% |
| Honoraria | $519,853 | 233 | 11.0% |
| Food and Beverage | $425,422 | 14,787 | 9.0% |
| Travel and Lodging | $420,574 | 1,127 | 8.9% |
| Consulting Fee | $384,222 | 137 | 8.1% |
| Space rental or facility fees (teaching hospital only) | $86,575 | 57 | 1.8% |
| Education | $1,325 | 214 | 0.0% |
Payments by Type
General
$2.7M
17,041 transactions
Research
$2.0M
1,013 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia HPP | Alexion Pharmaceuticals, Inc. | $664,001 | 0 |
| An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia HPP | Alexion Pharmaceuticals, Inc. | $589,901 | 0 |
| An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | Alexion Pharmaceuticals, Inc. | $402,201 | 0 |
| Open-Label Study of Asfotase Alfa in Infants and Children 5 Years of Age With Hypophosphatasia HPP | Alexion Pharmaceuticals, Inc. | $265,409 | 0 |
| Hypophosphatasemia in Duchenne muscular dystrophy | Alexion Pharmaceuticals, Inc. | $44,325 | 0 |
| A Phase 4, Randomized, Multicenter, Open-Label, 2-Dosage Regimen, Safety and Tolerability, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia | Alexion Pharmaceuticals, Inc. | $24,631 | 0 |
| Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Nave Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome aHUS | Alexion Pharmaceuticals, Inc. | $12,261 | 0 |
| Study of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency MOCD Type A | Alexion Pharmaceuticals, Inc. | $11,300 | 0 |
| A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome aHUS | Alexion Pharmaceuticals, Inc. | $9,805 | 0 |
| Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia HPP | Alexion Pharmaceuticals, Inc. | $9,340 | 0 |
| An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | $3,992 | 0 |
Top Doctors Receiving Payments for Strensiq — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Endocrinology, Diabetes & Metabolism | Phoenix, AZ | $25,154 | 103 |
| , MD | Clinical Genetics (M.D.) | Phoenix, AZ | $23,464 | 36 |
| , M.D | Clinical Genetics (M.D.) | New Orleans, LA | $22,012 | 53 |
| , MD | Endocrinology, Diabetes & Metabolism | Columbus, OH | $21,672 | 31 |
| , MD | Pediatric Endocrinology | Vanderbilt Hospital, TN | $20,751 | 23 |
| , M.D | Pediatric Orthopaedic Surgery | San Antonio, TX | $19,029 | 43 |
| , MD | Pediatric Endocrinology | Springfield, MA | $17,252 | 28 |
| , MD. MPH | Pediatric Nephrology | San Juan, PR | $16,684 | 32 |
| , DDS | Pediatric Dentistry | Cottonwood, AZ | $15,320 | 27 |
| , M.D | Clinical Genetics (M.D.) | Cincinnati, OH | $15,242 | 19 |
| , MD | Rheumatology | Franklin, WI | $14,861 | 26 |
| , MD | Clinical Genetics (M.D.) | Los Angeles, CA | $14,771 | 12 |
| , M.D | Pediatric Gastroenterology | Tucson, AZ | $13,570 | 20 |
| , MD | Rheumatology | Tustin, CA | $13,498 | 28 |
| , M.D | Rheumatology | Pittsburgh, PA | $12,792 | 24 |
| , MD | Endocrinology, Diabetes & Metabolism | New York, NY | $12,291 | 20 |
| , M.D | Endocrinology, Diabetes & Metabolism | Spokane, WA | $11,601 | 35 |
| , MD | Pediatric Nephrology | Chicago, IL | $11,571 | 13 |
| William Wilcox | Clinical Genetics (M.D.) | Los Angeles, CA | $11,186 | 10 |
| , M.D | Pediatrics | Baltimore, MD | $10,082 | 21 |
| , MD | Clinical Genetics (M.D.) | Wilmington, DE | $9,559 | 11 |
| , MD | Internal Medicine | Daly City, CA | $9,427 | 28 |
| , MD | Pediatrics | Little Rock, AR | $9,021 | 15 |
| Tamir Miloh | — | Phoenix, AZ | $8,575 | 4 |
| , MD, MPH | Pediatrics | New York, NY | $8,486 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.7M
- Total Doctors 7,562
- Transactions 18,054
About Strensiq
Strensiq is a drug associated with $4.7M in payments to 7,562 healthcare providers, recorded across 18,054 transactions in the CMS Open Payments database. The primary manufacturer is Alexion Pharmaceuticals, Inc..
Payment data is available from 2017 to 2021. In 2021, $214,014 was paid across 3,825 transactions to 2,393 doctors.
The most common payment nature for Strensiq is "Unspecified" ($2.0M, 43.1% of total).
Strensiq is associated with 11 research studies, including "Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia HPP" ($664,001).